Evdoxia Kyriazopoulou , George N Dalekos, Symeon Metallidis, Garyphalia Poulakou, Ilias C Papanikolaou, Vasiliki Tzavara, Katerina Argyraki, Zoi Alexiou, Periklis Panagopoulos, Michael Samarkos, George Chrysos, Aikaterini Tseliou, Haralampos Milionis, Styliani Sympardi, Anil Vasishta, Evangelos J. Giamarellos-Bourboulis

Shock 2024 Mar 1;61(3):395-399.
DOI: 10.1097/SHK.0000000000002315View article 🡆

Funding

This study was supported in part by the Hellenic Institute for the Study of Sepsis, in part by Swedish Orphan BioVitrum AB and in part by Joinstar, China. GND has received research grants from Gilead, served as advisor/lecturer for Ipsen, Pfizer, Genkyotex, Sanofi, Sobi and as PI for Amyndas Pharmaceuticals, Intercept Pharma, CymaBay Therapeutics, Genkyotex, Novo Nordisk, Pfizer, Regulus Therapeutics, Sobi, and Tiziana Life Sciences GP has received honoraria and/or consulting fees by Astra-Zeneca, Gilead, GSK, Menarini, MSD, Norma, Pfizer and SOBI and research grants by the University of Minnesota/University College London, the Hellenic Institute for the Study of Sepsis, Bausch, Roche, Xenothera, FabNTech and Pfizer. HΜ reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. EJGΒ has received honoraria from Abbott Products Operations, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi and Xbiotech Inc; independent educational grants from Abbott Products Operations, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Sobi and Xbiotech Inc.; and funding from the Horizon 2020 Marie Skłodowska-Curie International Training Network “the European Sepsis Academy” (granted to the National and Kapodistrian University of Athens), the Horizon 2020 European Grants ImmunoSep and RISCinCOVID and the Horizon Health grant EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).

Keywords: Biomarker; heparin-binding protein; mortality; outcome; COVID-19

Related study: SAVE